Women's Health · Nausea and Vomiting in PregnancyRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Doxylamine Succinate and Pyridoxine Hydrochloride

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:32:51 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the ANDA for Doxylamine Succinate and Pyridoxine Hydrochloride signifies a potential shift in the competitive landscape for treatments of nausea and vomiting in pregnancy. This could impact market dynamics and necessitate strategic adjustments from existing players in this therapeutic area. Regulatory context from FDA (FDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from established players in this therapeutic area. The strongest clinical anchor is Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health (ClinicalTrials.gov), moderate corpus alignment. In Women's Health · Nausea and Vomiting in Pregnancy, 8 regulatory and 2 competitive items passed relevance filtering for Pharmobedient.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may enhance Pharmobedient's position in the market for treating nausea and vomiting in pregnancy, competing with existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL) (FDA). Entity match (pharmobedient); Regulatory pathway relevance (nda). The acceptance of the ANDA indicates a step towards market entry, but ongoing monitoring of the review process is essential to anticipate any regulatory hurdles.

Key Risks

Elevated medium regulatory exposure for Pharmobedient could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Pharmobedient's entry into the market could challenge established products, potentially affecting their market share and pricing strategies.
Portfolio teams should assess the potential market impact and prepare for competitive responses from established players in this therapeutic area.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the ANDA review and any subsequent market entry timelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (pharmobedient); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Contribution of Immersive Virtual Reality to Standardized Rehabilitation Program for Upper Limb Chronic Pain: A Single-Case Experimental Design Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Controls and Healthy Vasculature Initiative
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in the relationship between mental symptoms in postmenopausal women and estrogen fluctuations.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pharmobedient
Doxylamine Succinate and Pyridoxine Hydrochloride

Commercial impact

medium

Pharmobedient's entry into the market could challenge established products, potentially affecting their market share and pricing strategies.

Regulatory impact

medium

The acceptance of the ANDA indicates a step towards market entry, but ongoing monitoring of the review process is essential to anticipate any regulatory hurdles.

What to watch

Monitor the progress of the ANDA review and any subsequent market entry timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.